Association of amino-terminal pro-brain natriuretic peptide with metabolic syndrome.

OBJECTIVE This study evaluated the relationship between individual components in metabolic syndrome (MetS) and amino-terminal pro-brain natriuretic peptide (NT-proBNP). METHODS A screening program for MetS in 2008 in Taiwan excluded subjects aged <30 years and pregnant women. Fasting glucose, insulin level, high-sensitivity C-reactive protein (hsCRP), and NT-proBNP were assessed. A propensity-score matching process was used to select subjects with and without MetS comparable in age, gender, body height, and serum creatinine levels. A multiple regression model was used to determine the association between individual components of MetS and NT-proBNP. Finally 270 subjects with MetS and another 270 matched subjects without MetS aged ≥30 years were included. RESULTS The subjects with MetS had higher uric acid and hsCRP, but not NT-proBNP. Multiple regression model showed that log (NT-proBNP) was positively associated with systolic blood pressure (β=0.002 per mmHg, p=0.013), but negatively associated with body mass index (β=-0.017 per kg/m(2), p=0.018), triglyceride (β=-0.00048 per mg/dL, p=0.020) and insulin level (β=-0.005 per mU/L, p=0.005). Log (NT-proBNP) was neutral to waist circumference, fasting glucose, high-density lipoprotein cholesterol, and diastolic blood pressure. CONCLUSION MetS was not associated with serum NT-proBNP concentrations due to the contradictory effects of each component.

[1]  H. Çelik,et al.  N-terminal pro-brain natriuretic peptide in cases with metabolic syndrome and its relationship with components of metabolic syndrome and left ventricular mass index. , 2009, Clinical biochemistry.

[2]  H. Kuo,et al.  Confirming a Biological Pathway in the Metabolic Syndrome—Insight from the NHANES 1999–2002 , 2008, Obesity.

[3]  Juey-Jen Hwang,et al.  Illustrating the roles of C-reactive protein in the development of the metabolic syndrome in women--a cross-racial validation. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[4]  N. Chi,et al.  Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis , 2008, The Lancet.

[5]  Ç. Yenisey,et al.  The role of N terminal pro-brain natriuretic peptide in the evaluation of left ventricular diastolic dysfunction: correlation with echocardiographic indexes in hypertensive patients , 2008, The International Journal of Cardiovascular Imaging.

[6]  D. Levy,et al.  Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals , 2007, Circulation.

[7]  R. D'Agostino,et al.  Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.

[8]  M. Drazner,et al.  Impact of Body Mass and Body Composition on Circulating Levels of Natriuretic Peptides: Results From the Dallas Heart Study , 2005, Circulation.

[9]  T. Jørgensen,et al.  N-Terminal Pro Brain Natriuretic Peptide Is Inversely Related to Metabolic Cardiovascular Risk Factors and the Metabolic Syndrome , 2005, Hypertension.

[10]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[11]  J. Hollander,et al.  Relationship between obesity and B-type natriuretic peptide levels. , 2004, Archives of internal medicine.

[12]  P. Savage,et al.  Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. , 2004, Diabetes.

[13]  E. Frohlich,et al.  Obesity and suppressed B-type natriuretic peptide levels in heart failure. , 2004, Journal of the American College of Cardiology.

[14]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[15]  R. Busse,et al.  Involvement of a cGMP-dependent Pathway in the Natriuretic Peptide-mediated Hormone-sensitive Lipase Phosphorylation in Human Adipocytes* , 2003, Journal of Biological Chemistry.

[16]  James E. Evans,et al.  Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.

[17]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[18]  P. Kalra,et al.  Regulation of lipolysis: natriuretic peptides and the development of cachexia. , 2002, International journal of cardiology.

[19]  RudolfBerger,et al.  B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002 .

[20]  R. Berger,et al.  B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002, Circulation.

[21]  D. Barnett,et al.  Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction , 1999 .

[22]  P. Poole‐Wilson,et al.  Uric acid in chronic heart failure: a marker of chronic inflammation. , 1998, European heart journal.

[23]  P. Dessı̀-Fulgheri,et al.  Expression of natriuretic peptide receptors in human adipose and other tissues , 1996, Journal of endocrinological investigation.

[24]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. , 1992, Journal of hypertension.

[25]  神田 秀幸.  What factors are associated with high plasma B-type natriuretic peptide levels in a general Japanese population? , 2005 .

[26]  S. Anker,et al.  Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. , 2000, Drugs.

[27]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. , 1992, Journal of hypertension.